{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:25:34Z","timestamp":1769826334226,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bulcan.2024.03.010","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:30:08Z","timestamp":1744284608000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ost\u00e9osarcome et sarcome d\u2019Ewing r\u00e9currents ou r\u00e9fractaires\u00a0\u2013\u00a0Directives fran\u00e7aises des groupes FSG\/NETSARC et GroupOs"],"prefix":"10.1016","volume":"112","author":[{"given":"Mehdi","family":"Brahmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Toulmonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixtine","family":"De Percin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Gantzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Marec-Berard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Claude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Tlemsani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bulcan.2024.03.010_bib0005","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3\u00a0trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.03.010_bib0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/pbc.25360","article-title":"Multiple relapses in high-grade osteosarcoma: when to stop aggressive therapy?","volume":"62","author":"Tamamyan","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.03.010_bib0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11912-013-0321-9","article-title":"The adolescent and young adult with cancer: state of the art - bone tumors","volume":"15","author":"Rainusso","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.bulcan.2024.03.010_bib0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","article-title":"Osteosarcoma treatment\u2013Where do we stand? A state of the art review","volume":"40","author":"Luetke","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.bulcan.2024.03.010_bib0025","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1200\/JCO.1994.12.12.2614","article-title":"Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy","volume":"12","author":"Tabone","year":"1994","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.03.010_bib0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-1-4419-0284-9_15","article-title":"Osteosarcoma: the COSS experience","volume":"152","author":"Bielack","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"18","key":"10.1016\/j.bulcan.2024.03.010_bib0040","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.ejca.2005.08.026","article-title":"Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27\u00a0year experience at Rizzoli Institute, Italy","volume":"41","author":"Bacci","year":"2005","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.03.010_bib0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2010.11.036","article-title":"Survival after recurrent osteosarcoma: data from 3\u00a0European Osteosarcoma Intergroup (EOI) randomized controlled trials","volume":"47","author":"Gelderblom","year":"2011","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.03.010_bib0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2003.03.141","article-title":"Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival","volume":"21","author":"Ferrari","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.03.010_bib0055","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00259-017-3698-0","article-title":"The role of 18F-FDG PET\/CT in the detection of osteosarcoma recurrence","volume":"44","author":"Angelini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","volume":"150","author":"Pasqualini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.bulcan.2024.03.010_bib0065","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1200\/JCO.21.01152","article-title":"Phase I or II study of Ribociclib in combination with Topotecan-Temozolomide or Everolimus in children with advanced malignancies: Arms A and B of the AcS\u00e9-ESMART Trial","volume":"39","author":"Bautista","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.03.010_bib0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1010-7940(99)00098-6","article-title":"Excision of pulmonary metastases of osteogenic sarcoma of the limbs","volume":"15","author":"Antunes","year":"1999","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"10.1016\/j.bulcan.2024.03.010_bib0075","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.1994.12.9.1849","article-title":"Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases","volume":"12","author":"Ward","year":"1994","journal-title":"JCO"},{"issue":"14","key":"10.1016\/j.bulcan.2024.03.010_bib0080","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.28111","article-title":"Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience","volume":"119","author":"Leary","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2024.03.010_bib0085","doi-asserted-by":"crossref","first-page":"e27792","DOI":"10.1002\/pbc.27792","article-title":"Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?","volume":"66","author":"Palmerini","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.03.010_bib0090","doi-asserted-by":"crossref","first-page":"17480","DOI":"10.1038\/s41598-017-14521-7","article-title":"Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73\u00a0patients","volume":"7","author":"Yu","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bulcan.2024.03.010_bib0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/08880018.2014.926469","article-title":"Radiofrequency ablation of metastases from osteosarcoma in patients under 25\u00a0years: the SCFE experience","volume":"32","author":"Saumet","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2019.11.007","article-title":"A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma","volume":"125","author":"Marec-Berard","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2024.03.010_bib0105","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.03.010_bib0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","article-title":"Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial","volume":"20","author":"Goorin","year":"2002","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2024.03.010_bib0115","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.24368","article-title":"Phase 2\u00a0trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients","volume":"115","author":"Berger","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12885-016-2312-3","article-title":"Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone","volume":"16","author":"Palmerini","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2024.03.010_bib0125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/pbc.25035","article-title":"Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience","volume":"61","author":"Song","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.03.010_bib0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2\u00a0study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.03.010_bib0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2\u00a0trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.03.010_bib0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.03.010_bib0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2\u00a0clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.03.010_bib0150","doi-asserted-by":"crossref","first-page":"100250","DOI":"10.1016\/j.esmoop.2021.100250","article-title":"Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)","volume":"6","author":"Gaspar","year":"2021","journal-title":"ESMO Open"},{"issue":"32","key":"10.1016\/j.bulcan.2024.03.010_bib0155","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.2217\/fon-2021-0743","article-title":"OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed\/refractory osteosarcoma","volume":"17","author":"Gaspar","year":"2021","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0160","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1200\/JCO.2020.38.15_suppl.11522","article-title":"IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I\/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort","volume":"38","author":"Palmerini","year":"2020","journal-title":"JCO"},{"issue":"10362","key":"10.1016\/j.bulcan.2024.03.010_bib0165","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3\u00a0trial","volume":"400","author":"Brennan","year":"2022","journal-title":"The Lancet"},{"issue":"20","key":"10.1016\/j.bulcan.2024.03.010_bib0170","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99\u00a0trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.03.010_bib0175","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.21618","article-title":"Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group","volume":"51","author":"Leavey","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.03.010_bib0180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.03.010_bib0185","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","article-title":"The European MAPPYACTS Trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies","volume":"12","author":"Berlanga","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bulcan.2024.03.010_bib0190","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pbc.20719","article-title":"Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors","volume":"47","author":"Hunold","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.03.010_bib0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2024.03.010_bib0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1634\/theoncologist.2010-0265","article-title":"Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003","volume":"17","author":"Fox","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bulcan.2024.03.010_bib0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21917","article-title":"Response to high-dose ifosfamide in patients with advanced\/recurrent Ewing sarcoma","volume":"52","author":"Ferrari","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.03.010_bib0210","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cam4.3712","article-title":"Systematic review of phase-I\/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research","volume":"10","author":"Felix","year":"2021","journal-title":"Cancer Med"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0215","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1200\/JCO.2019.37.15_suppl.11007","article-title":"Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma","volume":"37","author":"McCabe","year":"2019","journal-title":"JCO"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0220","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","article-title":"Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"38","author":"McCabe","year":"2020","journal-title":"JCO"},{"issue":"17_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0225","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2","article-title":"Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"40","author":"McCabe","year":"2022","journal-title":"JCO"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0230","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1200\/JCO.2021.39.15_suppl.10010","article-title":"Phase 2\u00a0trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622)","volume":"39","author":"Akshintala","year":"2021","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.bulcan.2024.03.010_bib0235","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cam4.5044","article-title":"A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024\u00a0trial results","volume":"12","author":"Attia","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0240","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41416-023-02413-9","article-title":"Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study","author":"Duffaud","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.03.010_bib0245","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/1471-2407-14-813","article-title":"Phase IIstudy of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy","volume":"14","author":"Choy","year":"2014","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2024.03.010_bib0250","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.33349","article-title":"SARC025\u00a0arms 1\u00a0and 2: a phase 1\u00a0study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma","volume":"127","author":"Chugh","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2024.03.010_bib0255","doi-asserted-by":"crossref","first-page":"e28073","DOI":"10.1002\/pbc.28073","article-title":"Phase 1\/2\u00a0trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a Children's Oncology Group Phase 1\u00a0Consortium study (ADVL1411)","volume":"67","author":"Schafer","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2024.03.010_bib0260","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","article-title":"A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies","volume":"137","author":"Federico","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2024.03.010_bib0265","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.22.01815","article-title":"Randomized Phase III Trial of Ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing Sarcoma: a report from the Children's Oncology Group","volume":"41","author":"DuBois","year":"2023","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2024.03.010_bib0270","doi-asserted-by":"crossref","first-page":"e23507","DOI":"10.1200\/JCO.2022.40.16_suppl.e23507","article-title":"Phase 2\u00a0trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma","volume":"40","author":"Shulman","year":"2022","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.bulcan.2024.03.010_bib0275","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pbc.25042","article-title":"The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma","volume":"61","author":"Rasper","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.03.010_bib0280","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/pbc.25388","article-title":"Post-relapse survival in patients with Ewing sarcoma","volume":"62","author":"Ferrari","year":"2015","journal-title":"Pediatr Blood Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T20:01:32Z","timestamp":1749240092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0007455125000827"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.03.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ost\u00e9osarcome et sarcome d\u2019Ewing r\u00e9currents ou r\u00e9fractaires\u00a0\u2013\u00a0Directives fran\u00e7aises des groupes FSG\/NETSARC et GroupOs","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}